Glycogen synthase kinase-3β2 has lower phosphorylation activity to tau than glycogen synthase kinase-3β1

DOI Web Site Web Site 被引用文献1件 参考文献23件
  • Saeki Kazunori
    Department of Biochemistry, Faculty of Pharmaceutical Science, Tokyo University of Science
  • Machida Mayumi
    Department of Biochemistry, Faculty of Pharmaceutical Science, Tokyo University of Science
  • Kinoshita Yutaro
    Department of Biochemistry, Faculty of Pharmaceutical Science, Tokyo University of Science
  • Takasawa Ryoko
    Department of Biochemistry, Faculty of Pharmaceutical Science, Tokyo University of Science
  • Tanuma Sei-ichi
    Department of Biochemistry, Faculty of Pharmaceutical Science, Tokyo University of Science Genome & Drug Research Center, Tokyo University of Science

書誌事項

タイトル別名
  • Glycogen Synthase Kinase-3.BETA.2 Has Lower Phosphorylation Activity to Tau than Glycogen Synthase Kinase-3.BETA.1
  • Glycogen synthase kinase 3 v 2 has lower phosphorylation activity to tau than glycogen synthase kinase 3 v 1

この論文をさがす

抄録

Glycogen synthase kinase-3β (GSK-3β) is a serine/threonine kinase that phosphorylate protein substrates involved in Alzheimer's disease (AD), such as microtubule-associated protein tau and amyloid precursor protein (APP). GSK-3β consists of two splice variants; the major short form (GSK-3β1) distributes in many organs and the minor long form (GSK-3β2), whose structural difference is the insert of only 13 amino acid residues to the C-terminal side of the catalytic site of GSK-3β1, is present in central nervous system. However, the physiological significances of the two variants are unclear. Here we examined whether the phosphorylation activities of two variants to tau and APP are different in cells. We found that GSK-3β2 has lower phosphorylation activity to tau at AD-relevant epitope (Ser396) than GSK-3β1 in cells, whereas the two variants exhibit equivalent levels of phosphorylation activities to APP. Recombinant GSK-3β2 has also lower phosphorylation activity to tau than GSK-3β1 in vitro, although the phosphorylation activities of the two variants to a synthetic peptide substrate pGS-2 are comparable. Furthermore, the deletion of the C-terminal tail (CT) of GSK-3β2 resulted in considerable reduction of tau phosphorylation activity as compared with GSK-3β1, suggesting that the lower phospho-rylation activity of GSK-3β2 to tau is attributed to weak interaction with tau through its unique higher-order structure of CT constructed by the 13 amino acids insertion. Such information may provide a clue for understanding of the physiological significance of the two splice variants of GSK-3β and a new insight into the regulation of tau phosphorylation in central nervous system.

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (23)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ